Determination That CLARITIN (Loratadine) Hives Relief Syrup, 5 Milligrams per 5 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, 5667-5668 [E6-1364]
Download as PDF
Federal Register / Vol. 71, No. 22 / Thursday, February 2, 2006 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Summaries of Medical and Clinical
Pharmacology Reviews of Pediatric
Studies; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
hsrobinson on PROD1PC71 with NOTICES
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of summaries of medical
and clinical pharmacology reviews of
pediatric studies submitted in
supplements for INVANZ (ertapenem),
KEPPRA (levetiracetam), TRILEPTAL
(Oxcarbazepine), and ZYVOX
(linezolid). These summaries are being
made available consistent with the Best
Pharmaceuticals for Children Act
(BPCA). For all pediatric supplements
submitted under the BPCA, the BPCA
requires FDA to make available to the
public a summary of the medical and
clinical pharmacology reviews of the
pediatric studies conducted for the
supplement.
ADDRESSES: Submit written requests for
single copies of the summaries to the
Division of Drug Information (HFD–
240), Center for Drug Evaluation and
Research, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857. Please specify by
product name which summary or
summaries you are requesting. Send one
self-addressed adhesive label to assist
that office in processing your requests.
See the SUPPLEMENTARY INFORMATION
section for electronic access to the
summaries.
FOR FURTHER INFORMATION CONTACT:
Grace Carmouze, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 21, rm. 1613,
Silver Spring, MD 20993-0002, 301–
796–2200, carmouzeg@cder.fda.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
summaries of medical and clinical
pharmacology reviews of pediatric
studies conducted for INVANZ
(ertapenem), KEPPRA (levetiracetam),
TRILEPTAL (Oxcarbazepine), and
ZYVOX (linezolid). The summaries are
being made available consistent with
section 9 of the BPCA (Public Law 107–
109). Enacted on January 4, 2002, the
BPCA reauthorizes, with certain
important changes, the pediatric
exclusivity program described in section
505A of the Federal Food, Drug, and
VerDate Aug<31>2005
15:26 Feb 01, 2006
Jkt 208001
Cosmetic Act (21 U.S.C. 355a). Section
505A permits certain applications to
obtain 6 months of marketing
exclusivity if, in accordance with the
requirements of the statute, the sponsor
submits requested information relating
to the use of the drug in the pediatric
population.
One of the provisions the BPCA
added to the pediatric exclusivity
program pertains to the dissemination of
pediatric information. Specifically, for
all pediatric supplements submitted
under the BPCA, the BPCA requires
FDA to make available to the public a
summary of the medical and clinical
pharmacology reviews of pediatric
studies conducted for the supplement
(21 U.S.C. 355a(m)(1)). The summaries
are to be made available not later than
180 days after the report on the
pediatric study is submitted to FDA (21
U.S.C. 355a(m)(1)). Consistent with this
provision of the BPCA, FDA has posted
on the Internet at https://www.fda.gov/
cder/pediatric/index.htm summaries of
medical and clinical pharmacology
reviews of pediatric studies submitted
in supplements for INVANZ
(ertapenem), KEPPRA (levetiracetam),
TRILEPTAL (Oxcarbazepine), and
ZYVOX (linezolid). Copies are also
available by mail (see ADDRESSES).
II. Electronic Access
Persons with access to the Internet
may obtain the document at https://
www.fda.gov/cder/pediatric/index.htm.
Dated: January 24, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–1366 Filed 2–1–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005P–0096]
Determination That CLARITIN
(Loratadine) Hives Relief Syrup, 5
Milligrams per 5 Milliliters, Was Not
Withdrawn From Sale for Reasons of
Safety or Effectiveness
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) has determined
that CLARITIN (loratadine) Hives Relief
syrup, 5 milligrams (mg) per (/) 5
milliliters (mL), was not withdrawn
from sale for reasons of safety or
effectiveness. This determination will
allow FDA to approve abbreviated new
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
5667
drug applications (ANDAs) for
loratadine hives relief syrup, 5 mg/5mL.
FOR FURTHER INFORMATION CONTACT:
Tawni B. Schwemer, Center for Drug
Evaluation and Research (HFD–7), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–594–
2041.
SUPPLEMENTARY INFORMATION: In 1984,
Congress enacted the Drug Price
Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98–417)
(the 1984 amendments), which
authorized the approval of duplicate
versions of drug products approved
under an ANDA procedure. ANDA
sponsors must, with certain exceptions,
show that the drug for which they are
seeking approval contains the same
active ingredient in the same strength
and dosage form as the ‘‘listed drug,’’
which is typically a version of the drug
that was previously approved. Sponsors
of ANDAs do not have to repeat the
extensive clinical testing otherwise
necessary to gain approval of a new
drug application (NDA). The only
clinical data required in an ANDA are
data to show that the drug that is the
subject of the ANDA is bioequivalent to
the listed drug.
The 1984 amendments include what
is now section 505(j)(7) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
355(j)(7)), which requires FDA to
publish a list of all approved drugs.
FDA publishes this list as part of the
‘‘Approved Drug Products With
Therapeutic Equivalence Evaluations,’’
which is generally known as the
‘‘Orange Book.’’ Under FDA regulations,
drugs are withdrawn from the list if the
agency withdraws or suspends approval
of the drug’s NDA or ANDA for reasons
of safety or effectiveness or if FDA
determines that the listed drug was
withdrawn from sale for reasons of
safety or effectiveness (§ 314.162 (21
CFR 314.162)).
Under § 314.161(a)(1) (21 CFR
314.161(a)(1)), the agency must
determine whether a listed drug was
withdrawn from sale for reasons of
safety or effectiveness before an ANDA
that refers to that listed drug may be
approved. FDA may not approve an
ANDA that does not refer to a listed
drug.
CLARITIN (loratadine) Hives Relief
syrup, 5 mg/5 mL, is the subject of
approved NDA 20–641 held by Schering
Corp. (now Schering-Plough Healthcare
Products) (Schering). In January 2002,
Schering submitted a supplemental
NDA for the over-the-counter (OTC) use
of CLARITIN (loratadine) syrup for the
relief of itching due to hives (urticaria),
to be marketed under the trade name
E:\FR\FM\02FEN1.SGM
02FEN1
hsrobinson on PROD1PC71 with NOTICES
5668
Federal Register / Vol. 71, No. 22 / Thursday, February 2, 2006 / Notices
CLARITIN Hives Relief. FDA approved
this trade name and indication for OTC
use under NDA 20–641 on November
19, 2003. Schering has not marketed the
5-mg/5-mL strength of Claritin Hives
Relief syrup.
In a citizen petition dated February
23, 2005 (Docket No. 2005P–0096),
submitted under 21 CFR 10.30, Silarx
Pharmaceuticals, Inc. (Silarx), requested
that the agency determine, as described
in § 314.161, whether CLARITIN
(loratadine) Hives Relief syrup, 5 mg/5
mL, was withdrawn from sale for
reasons of safety or effectiveness. The
agency has determined that Schering’s
CLARITIN (loratadine) Hives Relief
syrup, 5 mg/5 mL, approved under NDA
20–641, was not withdrawn from sale
for reasons of safety or effectiveness. To
date, Schering has not marketed the 5mg/5-mL strength of its CLARITIN
(loratadine) Hives Relief syrup. In
previous instances (see e.g., the Federal
Register of December 30, 2002 (67 FR
79640 at 79641) (addressing a relisting
request for Diazepam Autoinjector)), the
agency has determined that, for
purposes of §§ 314.161 and 314.162,
never marketing an approved drug
product is equivalent to withdrawing
the drug from sale.
FDA has reviewed its files for records
concerning the withdrawal of CLARITIN
(loratadine) Hives Relief syrup, 5 mg/5
mL. There is no indication that the
decision not to market CLARITIN
(loratadine) Hives Relief syrup, 5 mg/5
mL, commercially is a function of safety
or effectiveness concerns, and no data or
information has been submitted to the
docket concerning the reason for which
CLARITIN (loratadine) Hives Relief
syrup, 5 mg/5 mL was withdrawn from
sale. The identical formulation and
strength is currently marketed OTC as
Claritin syrup for the temporary relief of
symptoms due to hay fever or other
respiratory allergies: runny nose,
sneezing, itching, watery eyes, and
itching of the nose or throat. FDA is not
aware of information that would
indicate that Claritin Hives Relief syrup
was withdrawn from sale for reasons of
safety or effectiveness.
For the reasons outlined in this
document, FDA has determined that
Schering’s CLARITIN (loratadine) Hives
Relief syrup, 5 mg/5 mL, was not
withdrawn from sale for reasons of
safety or effectiveness. Accordingly, the
agency will continue to list CLARITIN
(loratadine) Hives Relief syrup, 5 mg/5
mL, in the ‘‘Discontinued Drug Product
List’’ section of the Orange Book. The
‘‘Discontinued Drug Product List’’
delineates, among other items, drug
products that have been discontinued
from marketing for reasons other than
VerDate Aug<31>2005
15:26 Feb 01, 2006
Jkt 208001
safety and effectiveness. ANDAs that
refer to CLARITIN (loratadine) Hives
Relief syrup, 5 mg/5 mL, may be
approved by the agency.
Dated: January 24, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–1364 Filed 2–1–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004E–0394]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; ALOXI
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) has determined
the regulatory review period for ALOXI
and is publishing this notice of that
determination as required by law. FDA
has made the determination because of
the submission of an application to the
Director of Patents and Trademarks,
Department of Commerce, for the
extension of a patent that claims that
human drug product.
ADDRESSES: Submit written comments
and petitions to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.fda.gov/dockets/ecomments.
FOR FURTHER INFORMATION CONTACT:
Claudia V. Grillo, Office of Regulatory
Policy (HFD–013), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 240–453–6681.
SUPPLEMENTARY INFORMATION: The Drug
Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98–
417) and the Generic Animal Drug and
Patent Term Restoration Act (Public
Law 100–670) generally provide that a
patent may be extended for a period of
up to 5 years so long as the patented
item (human drug product, animal drug
product, medical device, food additive,
or color additive) was subject to
regulatory review by FDA before the
item was marketed. Under these acts, a
product’s regulatory review period
forms the basis for determining the
amount of extension an applicant may
receive.
A regulatory review period consists of
two periods of time: a testing phase and
an approval phase. For human drug
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
products, the testing phase begins when
the exemption to permit the clinical
investigations of the drug becomes
effective and runs until the approval
phase begins. The approval phase starts
with the initial submission of an
application to market the human drug
product and continues until FDA grants
permission to market the drug product.
Although only a portion of a regulatory
review period may count toward the
actual amount of extension that the
Director of Patents and Trademarks may
award (for example, half the testing
phase must be subtracted, as well as any
time that may have occurred before the
patent was issued), FDA’s determination
of the length of a regulatory review
period for a human drug product will
include all of the testing phase and
approval phase as specified in 35 U.S.C.
156(g)(1)(B).
FDA recently approved for marketing
the human drug product ALOXI
(palonosetron hydrochloride). ALOXI is
indicated for the following: (1) The
prevention of acute nausea and
vomiting associated with initial or
repeat courses of moderately and highly
emetogenic cancer chemotherapy, and
(2) the prevention of delayed nausea
and vomiting associated with initial or
repeat courses of moderately and highly
emetogenic cancer chemotherapy.
Subsequent to this approval, the Patent
and Trademark Office received a patent
term restoration application for ALOXI
(U.S. Patent No. 5,202,333) from Roche
Palo Alto, LLC, and the Patent and
Trademark Office requested FDA’s
assistance in determining this patent’s
eligibility for patent term restoration. In
a letter dated October 19, 2004, FDA
advised the Patent and Trademark
Office that this human drug product had
undergone a regulatory review period
and that the approval of ALOXI
represented the first permitted
commercial marketing or use of the
product. Thereafter, the Patent and
Trademark Office requested that FDA
determine the product’s regulatory
review period.
FDA has determined that the
applicable regulatory review period for
ALOXI is 3,867 days. Of this time, 3,565
days occurred during the testing phase
of the regulatory review period, while
302 days occurred during the approval
phase. These periods of time were
derived from the following dates:
1. The date an exemption under
section 505 of the Federal Food, Drug,
and Cosmetic Act (the act) (21 U.S.C.
355) became effective: December 24,
1992. The applicant claims December
22, 1992, as the date the investigational
new drug application (IND) became
effective. However, FDA records
E:\FR\FM\02FEN1.SGM
02FEN1
Agencies
[Federal Register Volume 71, Number 22 (Thursday, February 2, 2006)]
[Notices]
[Pages 5667-5668]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-1364]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005P-0096]
Determination That CLARITIN (Loratadine) Hives Relief Syrup, 5
Milligrams per 5 Milliliters, Was Not Withdrawn From Sale for Reasons
of Safety or Effectiveness
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined that
CLARITIN (loratadine) Hives Relief syrup, 5 milligrams (mg) per (/) 5
milliliters (mL), was not withdrawn from sale for reasons of safety or
effectiveness. This determination will allow FDA to approve abbreviated
new drug applications (ANDAs) for loratadine hives relief syrup, 5 mg/
5mL.
FOR FURTHER INFORMATION CONTACT: Tawni B. Schwemer, Center for Drug
Evaluation and Research (HFD-7), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-594-2041.
SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price
Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417)
(the 1984 amendments), which authorized the approval of duplicate
versions of drug products approved under an ANDA procedure. ANDA
sponsors must, with certain exceptions, show that the drug for which
they are seeking approval contains the same active ingredient in the
same strength and dosage form as the ``listed drug,'' which is
typically a version of the drug that was previously approved. Sponsors
of ANDAs do not have to repeat the extensive clinical testing otherwise
necessary to gain approval of a new drug application (NDA). The only
clinical data required in an ANDA are data to show that the drug that
is the subject of the ANDA is bioequivalent to the listed drug.
The 1984 amendments include what is now section 505(j)(7) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which
requires FDA to publish a list of all approved drugs. FDA publishes
this list as part of the ``Approved Drug Products With Therapeutic
Equivalence Evaluations,'' which is generally known as the ``Orange
Book.'' Under FDA regulations, drugs are withdrawn from the list if the
agency withdraws or suspends approval of the drug's NDA or ANDA for
reasons of safety or effectiveness or if FDA determines that the listed
drug was withdrawn from sale for reasons of safety or effectiveness
(Sec. 314.162 (21 CFR 314.162)).
Under Sec. 314.161(a)(1) (21 CFR 314.161(a)(1)), the agency must
determine whether a listed drug was withdrawn from sale for reasons of
safety or effectiveness before an ANDA that refers to that listed drug
may be approved. FDA may not approve an ANDA that does not refer to a
listed drug.
CLARITIN (loratadine) Hives Relief syrup, 5 mg/5 mL, is the subject
of approved NDA 20-641 held by Schering Corp. (now Schering-Plough
Healthcare Products) (Schering). In January 2002, Schering submitted a
supplemental NDA for the over-the-counter (OTC) use of CLARITIN
(loratadine) syrup for the relief of itching due to hives (urticaria),
to be marketed under the trade name
[[Page 5668]]
CLARITIN Hives Relief. FDA approved this trade name and indication for
OTC use under NDA 20-641 on November 19, 2003. Schering has not
marketed the 5-mg/5-mL strength of Claritin Hives Relief syrup.
In a citizen petition dated February 23, 2005 (Docket No. 2005P-
0096), submitted under 21 CFR 10.30, Silarx Pharmaceuticals, Inc.
(Silarx), requested that the agency determine, as described in Sec.
314.161, whether CLARITIN (loratadine) Hives Relief syrup, 5 mg/5 mL,
was withdrawn from sale for reasons of safety or effectiveness. The
agency has determined that Schering's CLARITIN (loratadine) Hives
Relief syrup, 5 mg/5 mL, approved under NDA 20-641, was not withdrawn
from sale for reasons of safety or effectiveness. To date, Schering has
not marketed the 5-mg/5-mL strength of its CLARITIN (loratadine) Hives
Relief syrup. In previous instances (see e.g., the Federal Register of
December 30, 2002 (67 FR 79640 at 79641) (addressing a relisting
request for Diazepam Autoinjector)), the agency has determined that,
for purposes of Sec. Sec. 314.161 and 314.162, never marketing an
approved drug product is equivalent to withdrawing the drug from sale.
FDA has reviewed its files for records concerning the withdrawal of
CLARITIN (loratadine) Hives Relief syrup, 5 mg/5 mL. There is no
indication that the decision not to market CLARITIN (loratadine) Hives
Relief syrup, 5 mg/5 mL, commercially is a function of safety or
effectiveness concerns, and no data or information has been submitted
to the docket concerning the reason for which CLARITIN (loratadine)
Hives Relief syrup, 5 mg/5 mL was withdrawn from sale. The identical
formulation and strength is currently marketed OTC as Claritin syrup
for the temporary relief of symptoms due to hay fever or other
respiratory allergies: runny nose, sneezing, itching, watery eyes, and
itching of the nose or throat. FDA is not aware of information that
would indicate that Claritin Hives Relief syrup was withdrawn from sale
for reasons of safety or effectiveness.
For the reasons outlined in this document, FDA has determined that
Schering's CLARITIN (loratadine) Hives Relief syrup, 5 mg/5 mL, was not
withdrawn from sale for reasons of safety or effectiveness.
Accordingly, the agency will continue to list CLARITIN (loratadine)
Hives Relief syrup, 5 mg/5 mL, in the ``Discontinued Drug Product
List'' section of the Orange Book. The ``Discontinued Drug Product
List'' delineates, among other items, drug products that have been
discontinued from marketing for reasons other than safety and
effectiveness. ANDAs that refer to CLARITIN (loratadine) Hives Relief
syrup, 5 mg/5 mL, may be approved by the agency.
Dated: January 24, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6-1364 Filed 2-1-06; 8:45 am]
BILLING CODE 4160-01-S